C Diff Molecular

Vancomycin is a front-line antibiotic for the treatment of Clostridioides difficile infections. However, C. difficile isolates exhibiting reduced susceptibility

HA-CDI incidence has not increased during the COVID19 pandemic in two tertiary centers in Spain, in spite of a slightly higher antibiotic consumption during the COVID19 period in both hospitals. These findings suggest that, in the presence of strict infection control measures, hospital antibiotic co …

We evaluated whether hospitalized patients without diagnosed Clostridioides difficile infection (CDI) increased the risk for CDI among their family members after discharge. We used 2001-2017 US insurance claims data to compare monthly CDI incidence between persons in households with and without a fa …

We present the case of a 71-year-old male who suffered an episode of acute renal failure caused by the uncommon association of two different diseases (Clostridioides difficile infection and McKittrick-Wheelock syndrome). He presented with hypovolemic shock, severe hypokalemia, hyponatremia, m …

Reducing perioperative antibiotic use can mitigate this risk.

Correction for Paulick et al., "Characterization of Clostridioides difficile Isolates Available through the CDC & FDA Antibiotic Resistance Isolate Bank"

New research suggests that COVID-19 may have worsened antibiotic resistance in hospitals.

Antibiotic resistance happens when bacteria develop genetic mutations that allow them to survive an antibiotic. Here is a look at how this happens and how it can be prevented.

Abstract. We are host to an assembly of microorganisms that vary in structure and function along the length of the gut and from the lumen to the mucosa. This ec

Author Correction: Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection

Nature Reviews Gastroenterology & Hepatology - Clostridioides difficile infection has a notable health and economic burden worldwide. In this Review, the authors provide insights into the...

NCT04031469 (PCR-) and 04359836 (PCR+).

“RT @FfitzP: We need to hear this side of the #cdiff story @TAEscmid @ESCMID #ECCMID2022”

Microbiome restoration helps prevent C. diff spore germination—and can change the ending of the same frightening plot

Aim: To assess the impact of Clostridioides difficile infection on the course of COVID-19. Methods: The authors included 809 patients with COVID-19 in this retrospective study: 55 had C. difficile infection, 23 had C. difficile-negative antibiotic-associated diarrh …

In a mouse model, the product protected against C difficile without eliminating the antibiotic’s presence in the blood.

To determine epidemiology and a proper treatment regimen for extraintestinal C difficile infection, a greater accumulation of cases is necessary.

The SEASON GAP score is useful in ruling out CDI in patients with tube feeding, thus reducing unnecessary CD testing and antimicrobial use.

This article explores what we know so far about the role of the gut microbiota in diverticulitis and discusses two recent clinical trials on the role of probiotics in managing acute uncomplicated diverticulitis.

An uncommon case of monomicrobial Clostridioides difficile septicemia in a 63-year-old man was reported in Zhejiang, China. Once diagnosed, vancomycin treatment cleared the infections. The patient had no remarkable medical history, and the inspection showed no overt gastrointestinal symptoms, …

Patients with hepatic cirrhosis are more susceptible to Clostridioides difficile infection (CDI) and colonization with Clostridioides difficile (C. difficile). Asymptomatic C. difficile colonization is thought to predispose to subsequent CDI. However, the dynamic gut micr …

The incidence of rec CDI is ⬆️. After an initial episode, ⤴️35% have recurrence. ⤴️60% who have a recurrence have another one. Exposure to antibiotics is a critical modifiable risk factor. Most cases occur within 2 wks of antibiotic Rx. #CDiff #antibiotics #antibioticstewardship pic.twitter.com/NTgwYohGZ0— Satyendra Dhar, MD MHA FHM (@DharSaty) March 2, 2022

The technology platform could speed up the development of novel therapeutics to combat virulence.

C. difficile infection (CDI) is a highly inflammatory disease mediated by the production of two large toxins that weaken the intestinal epithelium and cause extensive colonic tissue damage. Antibiotic alternative therapies for CDI are urgently needed as current antibiotic regimens prolong the perturbation of the microbiota and lead to high disease recurrence rates. Inflammation is more closely correlated with CDI severity than bacterial burden, thus therapies that target the host response represent a promising yet unexplored strategy for treating CDI. Intestinal bile acids are key regulators of gut physiology that exert cytoprotective roles in cellular stress, inflammation and barrier integrity, yet the dynamics between bile acids and host cellular processes during CDI have not been investigated. Here we show that several bile acids are protective against apoptosis caused by C. difficile toxins in Caco-2 cells and that protection is dependent on conjugation. Out of 20 tested bile acids, taurine conjugated ursodeoxycholic acid (TUDCA) was the most potent inhibitor yet unconjugated UDCA did not alter toxin-induced apoptosis. TUDCA treatment decreased expression of genes in lysosome associated and cytokine signaling pathways. TUDCA did not affect C. difficile growth or toxin activity in vitro whereas UDCA significantly reduced toxin activity in a Vero cell assay and decreased tcdA gene expression. These results demonstrate that bile acid conjugation can have profound effects on C. difficile as well as the host and that conjugated and unconjugated bile acids may exert different therapeutic mechanisms against CDI.

Recurrent infections occurred in 23.9% of the 134-patient study.

Diarrhea is common, has several predictors, and prompts changes in patient care, is associated with longer time to discharge but not mortality.

The anaerobic bacterium Clostridioides difficile represents one of the most problematic pathogens, especially in hospitals. Dysbiosis has been proven to largely reduce colonization resistance against this intestinal pathogen. The beneficial effect of the microbiota is closely associated with …